Thomas Glanzmann News Today

Daniel Segarra: Hello, everyone, and welcome to Grifols Conference Call. Today, we will be sharing a business update on our first quarter financial results.

Grifols on track to close its strategic alliance with Haier in first half 2024 Both companies have completed the customary...

Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030 Barcelona, Spain, April 23, 2024 - Grifols , a global healthcare...

Grifols, a global manufacturer of plasma-based medicines headquartered in Barcelona, Spain, held a celebration to mark 50 years in Clayton, NC.Grifols acquired the Johnston County facility in 2011 from Talecris Biotherapeutics, turning Grifols into a top-three plasma-sector powerhouse. 

Grifols said on Thursday it had lowered its debt ratio in 2023 and was on track to reduce it further using funds from the $1.8 billion sale of its stake in Shanghai RAAS Blood Products which is...

BARCELONA (Reuters) -Spanish drug maker Grifols' top executive Thomas Glanzmann said on Thursday he will become non-executive chairman in 2025 as part of the beleaguered company's management overhaul. Glanzmann, who is currently both chief executive and executive chairman, had said earlier this month he would leave the CEO job on April 1, but remain executive chairman afterwards. Grifols shares on Spain's blue-chip index <.IBEX> were down 6.5% to 10.9 euros per share s...

Spanish pharmaceutical company Grifols said on Tuesday it had appointed Nacho Abia as a board member, following the announcement of his hiring as Chief Executive on Feb. 5....

Renta 4| Grifols (GRF) has announced the appointment of Nacho Abia as the new CEO, replacing Thomas Glanzmann who will continue in the role of executive

Renta 4| Grifols (GRF) has announced the appointment of Nacho Abia as the new CEO, replacing Thomas Glanzmann who will continue in the role of executive

MADRID (Reuters) -The European Central Bank has asked some lenders to detail their exposure to Spain's Grifols and its related entities, after the drugmaker was last week accused of manipulating its financial accounts by a short-seller, sources said. Grifols denies the accusations by Gotham City Research that it has manipulated its debt and earnings through transactions with a related entity, to the effect that its leverage ratio is nearly double what Grifols has reported. The ECB has in re...